Artisan Pharma, Inc. Completes Enrollment in 750-patient Phase 2b Study of ART-123 in Sepsis Patients with DIC
Published: Apr 29, 2010
WALTHAM, Mass.--(BUSINESS WIRE)--Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC. The clinical study enrolled 750 patients in over 150 sites worldwide.